Cardiac Fibrosis
The Fibroblast Awakens

Joshua G. Travers, Fadia A. Kamal, Jeffrey Robbins, Katherine E. Yutzey, Burns C. Blaxall

Abstract: Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart disease. Cardiac fibroblasts comprise an essential cell type in the heart that is responsible for the homeostasis of the extracellular matrix; however, upon injury, these cells transform to a myofibroblast phenotype and contribute to cardiac fibrosis. This remodeling involves pathological changes that include chamber dilation, cardiomyocyte hypertrophy and apoptosis, and ultimately leads to the progression to heart failure. Despite the critical importance of fibrosis in cardiovascular disease, our limited understanding of the cardiac fibroblast impedes the development of potential therapies that effectively target this cell type and its pathological contribution to disease progression. This review summarizes current knowledge regarding the origins and roles of fibroblasts, mediators and signaling pathways known to influence fibroblast function after myocardial injury, as well as novel therapeutic strategies under investigation to attenuate cardiac fibrosis. (Circ Res. 2016;118:1021-1040. DOI: 10.1161/CIRCRESAHA.115.306565.)

Key Words: disease progression ■ extracellular matrix ■ fibroblasts ■ fibrosis ■ heart failure ■ therapeutics

Heart failure, the clinical manifestation of numerous forms of cardiovascular disease, is a devastating disorder characterized by interstitial fibrosis, chamber remodeling, and reduced ventricular compliance. Heart disease remains the predominant cause of mortality in the United States, accounting for nearly 800,000 deaths per year.1 Furthermore, it presents a considerable economic burden, with estimated direct and indirect costs in 2011 of $320 billion and predictions suggesting that costs will rise to $918 billion by 2030.1 Despite substantial improvements in therapeutic strategies, cardiovascular disease remains the leading cause of death worldwide indicating an urgent need for innovative treatment strategies.

Nearly all etiologies of heart disease involve pathological myocardial remodeling characterized by excessive deposition of extracellular matrix (ECM) proteins by cardiac fibroblasts (CFs), which reduces tissue compliance and accelerates the progression to heart failure. The CF is an essential cell type, predominantly of embryonic epicardial and endothelial origins,2-4 which resides within the myocardial interstitium, epicardial and perivascular regions.5,6 Physiologically, CFs are responsible for homeostasis of the ECM, which provides a structural scaffold for cardiomyocytes, distributes mechanical forces through the cardiac tissue, and mediates electric conduction.6-8 Previously, identification of these cells was largely based on phenotypic observations; morphologically, fibroblasts are flat, spindle-shaped cells with multiple processes when propagated on tissue culture plastic. The cardiac cellular milieu can vary greatly depending on the species being examined and between healthy and injured myocardium.9 Although previous studies suggested that CFs accounted for the majority of cells within the adult rodent and human myocardium,7,9,10 recent reports with more accurate delineation of the CF population have proposed that CFs may comprise <20% of the total cell population in the adult murine heart, substantially less than previously suggested.2,11 Although it is now appreciated that a majority of resident fibroblasts originate from the embryonic epicardium,12,13 the contribution of various resident and infiltrating cells to the population of activated cardiac myofibroblasts remains under active investigation, including further refinement of specific molecular markers for CFs.

Unlike other organs, the heart has limited regenerative capacity after injury, and instead, repair processes involve the removal of necrotic cardiomyocytes followed by fibrotic scar tissue replacement that acts to preserve myocardial structural and functional integrity. To perform these functions, CFs within the connective tissue convert to their activated form, often known as myofibroblasts, which secrete elevated levels of ECM proteins to promote a profibrotic environment. Cardiac fibrosis provokes pathological changes that culminate in chamber dilatation, cardiomyocyte hypertrophy, and apoptosis, and ultimately lead to the development of congestive heart failure.14-16 Although the sources of these activated fibroblasts remain under intense investigation and debate, the refinement of molecular markers and the development of new techniques for lineage tracing are helping to enhance our understanding of their origins.2,4
Despite the pathophysiological importance of fibrosis in cardiovascular disease, the CF remains relatively mischaracterized and poorly understood; furthermore, there currently exist limited clinical interventions that effectively target this cell type and its pathological contributions to disease progression. Although recent progress has improved our understanding of the CF, the absence of a universal marker or method for the interpretation of results.17 This review summarizes current knowledge regarding the origin and role of the CF in development and disease, and presents recent advances toward novel therapeutic interventions targeting this critical cell population.

Role of CFs in Injury

The CF is now recognized for its fundamental contributions to the heart’s response to various forms of injury (Figure 1). In general, the critical phases of this response consist of inflammation, proliferation of nonmyocytes, and scar maturation, with the CF intimately involved in all of these processes. After an acute myocardial injury, the expression of various proinflammatory cytokines and profibrotic factors is upregulated in CFs, leading to increased proliferation of these cells and ultimately, the transition to the myofibroblast phenotype.18 During this maturation phase, myofibroblasts begin to secrete elevated levels of collagens and other ECM proteins. The purpose of this adaptive fibrosis is to maintain the structural integrity and pressure-generating capacity of the heart because a loss of integrity in the mechanical strength of the ventricle may lead to myocardial dysfunction or rupture. In the advanced phases of fibrotic scar formation, the tensile strength of collagen increases within the site of injury.19 In this setting, a subset of activated myofibroblasts acquire new phenotypic characteristics, including the expression of the contractile protein α-smooth muscle actin (α-SMA), and contribute to pathological cardiac remodeling.20,21 Although initially adaptive, these processes eventually lead to the development of adverse changes in ventricular structure and compliance, and a concurrent progression into overt heart failure.

Pathological cardiac remodeling is characterized by fibroblast accumulation and excessive deposition of ECM proteins, which leads to distorted organ architecture and has significant consequences on cardiac function.22 Fibrogenesis contributes to impaired cardiac function as fibrotic ECM increases ventricular stiffness and can lead to contractile dysfunction.23,24 In addition, excess ECM and fibroblasts impair mechano-electric coupling of cardiomyocytes, thus reducing cardiac contraction and increasing the risk of arrhythmogenesis and mortality.25,26 This pathological process can also include hypertrophy and dysfunction of cardiomyocytes via paracrine mechanisms, which further contribute to impaired cardiac function.27 Furthermore, inflammation and fibrosis within perivascular regions may decrease tissue availability to oxygen and nutrients and increase the pathological remodeling response.28

After the initial wound healing process in many tissues, a majority of collagen-secreting fibroblasts undergo apoptosis and leave a mature scar composed of cross-linked collagen and other matrix components.29 However, when this process persists in the heart, myofibroblasts within the cardiac scar tissue continue to release maladaptive proinflammatory and prohypertrophic signals, resulting in cardiomyocyte hypertrophy and necrosis followed by replacement fibrosis.30,31 Importantly, after an acute injury such as myocardial infarction (MI), activated fibroblasts not only increase the synthesis of ECM proteins at the site of injury but also within the healthy tissue remote from the immediate infarct.15,32 Commonly referred to as reactive fibrosis,33 This potentiates the pathophysiological response after acute myocardial injury by reducing chamber compliance and increasing stiffness of the ventricles.34 A portion of myofibroblasts remain embedded in mature cardiac scars long after the initial myocardial injury, probably because of a resistance to apoptosis, which perpetuates these pathological processes.34

Cardiac fibrosis can be categorized into 2 forms, namely reactive interstitial fibrosis or replacement fibrosis, each of which can be recapitulated by several models of heart failure.35,36 Transverse aortic constriction is an animal model of left ventricular pressure overload (similar to aortic stenosis) characterized initially by reactive interstitial fibrosis, an adaptive response to preserve cardiac structure and function, and followed by replacement fibrosis in areas of cardiomyocyte necrosis.37 In animal models of acute ischemic injury, such as MI or ischemia/reperfusion injuries, the initial injury is characterized by an immediate, robust inflammatory response, and extensive cardiomyocyte death; replacement fibrosis restores this region devoid of viable cardiomyocytes to prevent cardiac rupture.38 Cardiac fibrosis also occurs in the context of right ventricular volume overload that can result from congenital malformations, such as repaired tetralogy of Fallot or

Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK</td>
<td>activin receptor-like kinase</td>
</tr>
<tr>
<td>Ang II</td>
<td>angiotensin II</td>
</tr>
<tr>
<td>AT1R</td>
<td>ang II type 1 receptor</td>
</tr>
<tr>
<td>CF</td>
<td>cardiac fibroblast</td>
</tr>
<tr>
<td>CTGF/CCN2</td>
<td>connective tissue growth factor</td>
</tr>
<tr>
<td>CYR61/CCN1</td>
<td>cysteine-rich angiogenic inducer 61</td>
</tr>
<tr>
<td>EMT</td>
<td>epithelial–mesenchymal transition</td>
</tr>
<tr>
<td>ET-1</td>
<td>endothelin-1</td>
</tr>
<tr>
<td>FSP1</td>
<td>fibroblast-specific protein 1</td>
</tr>
<tr>
<td>GFP</td>
<td>green fluorescent protein</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein–coupled receptor</td>
</tr>
<tr>
<td>GRK2</td>
<td>GPCR kinase 2</td>
</tr>
<tr>
<td>IL-1β</td>
<td>interleukin-1β</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>MRTF</td>
<td>myocardin-related transcription factor</td>
</tr>
<tr>
<td>NOV/CCN3</td>
<td>nephroblastoma overexpressed</td>
</tr>
<tr>
<td>PDGFRα</td>
<td>platelet-derived growth factor receptor α</td>
</tr>
<tr>
<td>α-SMA</td>
<td>α-smooth muscle actin</td>
</tr>
<tr>
<td>SRF</td>
<td>serum response factor</td>
</tr>
<tr>
<td>TAK</td>
<td>TGF-β–activated kinase</td>
</tr>
<tr>
<td>TGF-β</td>
<td>transforming growth factor β</td>
</tr>
<tr>
<td>TRPC</td>
<td>transient receptor potential channel</td>
</tr>
<tr>
<td>VECad/Cdh5</td>
<td>vascular endothelial cadherin</td>
</tr>
</tbody>
</table>
pulmonary hypertension. In a mouse model of right ventricular volume overload, fibrosis is evident first in the subendocardial right ventricle, but relatively little is known of the cellular origins or molecular mechanisms of fibrosis in this context.40 These models represent critical yet differing recapitulations of human disease, and as such, show distinct functions of the fibroblast response to injury.39

**CF Markers and Limitations**

One major area of study is an attempt to quantify relative contributions of the various cardiac cell lineages to the CF population after injury. Such studies rely on molecular biomarkers, but experimental interpretation is difficult because this cell population can include fibroblasts, endothelial cells, pericytes, and immune cells. Further complicating this effort, although lineage-specific markers have long been established for several cell types within this group, robust markers of both quiescent CFs and activated cardiac myofibroblasts remain elusive. With numerous molecular markers now being recognized for their ability to identify particular populations of CFs, the controversy surrounding this cell population remains unresolved. In the heart, as with other organs, there is an increasing interest in the investigation of novel CF and myofibroblast markers, and transcriptomics is proving an effective method for the uncovering of new markers.41 Aside from the immediate benefits for cell identification, biomarkers in use for other organs, for example the kidney, can be used as tools to diagnose the progression of disease and also as novel therapeutic targets. Here, we present several commonly used molecular markers to identify quiescent and activated CFs, concerns about their use, and how the refinement of these markers may potentially provide for the identification of a purer fibroblast population (Table 1).

Among the first markers used to identify CFs was discoidin domain receptor 2, which acts as a receptor for several ECM proteins.48 Although expression is limited in other cell types, including endothelial cells, smooth muscle cells, and myocytes, it does not seem that all CFs are positive for discoidin domain receptor 2.9 Fibroblast-specific protein 1 (FSP1 and S100A4), one of the initial markers identified, was believed to be a reliable fibroblast indicator.49 FSP1 was commonly used to designate quiescent and activated CFs in myocardial injury, including pressure overload and infarction-induced fibrosis models. However, recent in vivo work using FSP1–green fluorescent protein (GFP) and FSP1 immunostaining has demonstrated that it is not fibroblast-specific, based on positive expression in several cell types, including a subset of immune and endothelial cells.5,42,50,51 Another marker used to identify CFs is thymus-cell antigen 1 (Thy1, CD90), a membrane glycoprotein expressed on the surface of CFs.44 Although this receptor does seem to be expressed on all CFs, other cell types are known to express thymus-cell antigen 1, including immune cells, lymphatic endothelial cells, and pericytes.68–70 Vimentin is an intermediate filament protein that has
been used extensively both in vitro and in vivo for the identification of fibroblasts because it is expressed in the majority of fibroblasts both in the healthy and in the injured myocardium. Although CFs are positive for vimentin, concerns with its expression in other cell types, including the endothelium, restrict its efficiency and specificity. In general, the major complications associated with many of the markers currently in use involve either expression in other cell types or limited expression in all forms of CFs.

The transcription factor TCF21 has been used successfully to trace the development of resident CFs from their epicardial precursors. In addition to its extensive expression during development, TCF21 is also broadly expressed in CFs both within interstitial and perivascular fibrotic regions in response to heart failure models of both pressure overload and ischemic etiologies. Importantly, TCF21 is not expressed in infiltrating immune cells identified by positive CD45 expression. In addition, the TCF21 transcription factor seems to be required for CF cell fate determination in development. The inducible TCF21mERCreER transgenic mouse line represents one of the more powerful inducible lines for the study of CFs in development and disease. In development, TCF21 is essential for the formation of CFs in utero, and the TCF21 signal remains active in adult mice, which enables this line to provide significant insight into the contribution of resident fibroblasts to the development of fibrosis in the injured heart.

Platelet-derived growth factor receptor α (PDGFRα) has emerged as a reasonable marker of CFs both during development and in healthy and injured adult tissues. It is also expressed in multiple other organs, including lung fibroblast lineages, oligodendrocyte progenitors, and bladder interstitial cells. In the heart, PDGFRα is robustly expressed in fibroblasts, with relatively limited expression in other cell types, including smooth muscle cells and possible expression in cardiac progenitor cells; it has been used for the development of an inducible Cre system, the PDGFRα-GFPCreERT2 knockin mouse line. This will likely prove a useful tool in characterizing CFs and their role in fibrosis. PDGFRβ has also been used as a marker of fibroblasts. However, expression of PDGFRβ has been observed in numerous other cell types including smooth muscle cells, pericytes, neurons, kidney mesangium, myoblasts, and muscle lineages, thus restricting its specificity and efficiency.

As CFs are likely the principal cells responsible for the secretion of ECM proteins, a new line of thinking involves the identification of CFs by the expression of markers of ECM production. As the predominant protein of the myocardial ECM, the Col1a1 promoter sequences linked to GFP has been used to create a reporter mouse for identification of CFs.
An inducible form of the collagen1α2 Cre driver has also been developed, allowing for both genetic lineage tracing of collagen1α2 Cre-positive cells and conditional gene deletion for functional studies. However, the expression of collagen is increasingly recognized as not being restricted solely to the fibroblast lineage. Positive collagen 1α1-GFP expression has been reported within cells of both the epicardium and the adventitia of large vessels, suggesting caution in the interpretation of fibroblast-centric conclusions from studies using these lines.

In addition to the molecular markers discussed above, several are expressed after the transition to the activated myofibroblast. Identification of myofibroblasts in many tissues has almost universally relied on the expression of the contractile protein αSMA. However, recent work using a pressure-overload model of heart disease showed that this marker is restricted to a subset of activated fibroblasts and is not expressed in all fibroblasts associated with fibrosis. Periostin is an ECM protein expressed in development, which is also robustly upregulated by activated CFs after injury. A periostin-Cre transgenic mouse line has been developed that expresses Cre under the control of the endogenous periostin promoter that is expressed in resident CFs and epicardial cells in the developing heart, making it well suited to developmental investigations. As periostin-Cre is robustly expressed within activated CFs/myofibroblasts and myocardial infarct sites after injury, it presents one of the more promising tools for lineage tracing and genetically manipulating CFs and myofibroblasts. The development of an inducible knockin system in periostin-expressing cells will likely be an enormously effective tool for the study of activated fibroblasts in disease. Of note, interstitial cells of the valves also express some of the ECM proteins that mark fibroblasts, such as collagen 1α1 and periostin. Overall, advancements in the identification and reliability of CF molecular biomarkers remain essential areas of research, and will eventually allow for a greater understanding of this critical cell type.

Sources of CFs in Disease

The source(s) of activated CFs that accumulate in response to various pathological insults remains somewhat unclear. In other organs, including the lung, kidney and liver in particular, the cellular and molecular mechanisms of fibrosis, and the origins and characteristics of myofibroblasts have also been extensively studied, yet some ambiguity remains. Lineage tracing studies have been critical to the development of fibrosis in a pressure-overload model of heart failure, as well as in a model of parabiosis. Although these data contradict some previous studies, they indicate that myofibroblast accumulation after injury predominantly results from the proliferation of resident fibroblasts. In addition, resident fibroblasts have been suggested as a feasible source of matrix-producing cells during fibrosis, which could identify them as an important potential target for antifibrotic therapies. Several studies have evaluated the contribution of alternative sources to the activated fibroblast population in pathological cardiac remodeling as individually outlined below.

Vascular Endothelium

Endothelial cells of the coronary vasculature have been proposed as contributors to the myofibroblast population after injury through endothelial–mesenchymal transition. Lineage tracing studies using the constitutive endothelial/hematopoietic restricted Tie1Cre mouse line have suggested that FSP1-positive cells contribute substantially to the fibroblast population in a pressure-overload model of heart failure. These endothelial cells are thought to acquire a fibroblast-like phenotype and respond to profibrotic stimuli in a manner similar to resident CFs. This phenotypic conversion involves the migration of these cells into the interstitium, where they exhibit typical myofibroblast markers and are believed to contribute to the fibrotic response. However, recent studies have demonstrated that, in addition to fibroblasts, FSP1 also marks a substantial number of immune cells. Furthermore, Tie1Cre is not specific to the endothelium, with fibroblasts being labeled in addition to immune cells and other cell types. In an attempt to resolve this controversy, several studies have since been performed using refined fibroblast markers, including tamoxifen-inducible Cre recombinase under the control of the vascular endothelial cadherin (VECad/Cdh5) promoter (VECad-Cre-ERT2), in concert with collagen-1α and PDGFRα as fibroblast markers. This was complemented by a study using the Tie2Cre mouse line to label and identify cells with endothelial origins. These studies concluded that, at least in the pressure-overload model of heart failure, the endothelium does not significantly contribute to the myofibroblast population.
Epicardium

Resident fibroblasts of the cardiac interstitium are now generally recognized to derive predominantly from cells of the embryonic epicardium. During development, these cells undergo epithelial–mesenchymal transition (EMT) under the influence of several growth factors; subsequently, a portion of these mesenchymal cells invade the myocardium to become the resident CFs. Signals regulating the transition of epicardial cells to fibroblasts are tightly regulated and factors known to influence this transition can include fibroblast growth factors and members of the transforming growth factor \( \beta \) (TGF-\( \beta \)) superfamily. Once these cells have undergone EMT, PDGF and TGF-\( \beta \) are thought to promote their transition into the CF phenotype. As seen during development, a subset of epicardial cells can undergo EMT to generate CFs after an acute cardiac injury. In pulmonary fibrosis, cells of the lung epithelium, particularly type II pneumocytes, play a key role in the initiation and propagation of fibrotic signaling in response to either endogenous or exogenous stress, leading to the activation of resident macrophages and fibroblasts. In addition, several studies have suggested that a heterogeneous pool of myofibroblasts may originate from EMT of cholangiocytes in hepatic fibrosis; however, new work has demonstrated that EMT may not play a significant role. Similarly, recent studies have indicated that cells of epicardial origin may contribute to myofibroblast accumulation after MI to aid in the fibrotic response; however, EMT does not seem to be functionally significant in the pressure-overload model of heart failure. These cells may present an interesting source of activated CFs, but more work is needed to characterize the particular functional contribution(s) of this cell type in vivo.

Perivascular Cells

Pericytes, which lie in the perivascular space of cardiac vessels, can differentiate into collagen-producing cells in models of dermal scarring and may contribute to the fibroblast population after cardiac injury. This cell type has been defined in other tissues, including the retina and kidneys, where they have demonstrated phenotypic and functional overlap with fibroblasts; however, they are more thoroughly characterized in the central nervous system. Pericytes surround the neurovasculature and interact with other cell types, including astrocytes and endothelial cells. Here, they maintain the blood–brain barrier and regulate angiogenesis, immune responses, and scar formation, which are affected by factors such as PDGF and TGF-\( \beta \). The integrity of retinal microvessels is particularly dependent on pericytes, as loss of retinal pericytes contributes to diabetic retinopathy through the formation of microaneurysms. Recent work has revealed the presence of Gli1+ mesenchymal stem cell-like cells within cardiac perivascular regions. Lineage tracing studies demonstrated that the proliferation of these resident cells after kidney, lung, liver, or cardiac injury generates myofibroblasts that contribute to organ fibrosis. Furthermore, ablation of these cells ameliorates cardiac fibrosis and preserves overall cardiac function in a pressure-overload model of heart failure and attenuates renal fibrosis after unilateral ureteral obstruction injury. Although these Gli1+ cells may not represent a distinct mesenchymal cell population, as they are...
also positive for several other markers including PDGFRα, these studies do indicate that perivascular cells seem to be an important source of cardiac myofibroblasts and may represent a potential therapeutic target for ameliorating cardiac and general organ fibrosis.107

**Hematopoietic Bone Marrow–Derived Progenitor Cells**

Bone marrow–derived progenitor cells are considered a potential source of fibroblasts in the fibrotic heart. This assertion is based on studies of GFP-labeled bone marrow transplants, which identified GFP-expressing cells within fibrotic regions after both pressure overload and ischemic myocardial injuries.42,108,109 It has been suggested that bone marrow–derived cells may account for up to 60% of all fibroblasts within the site of cardiac injury. However, this cell population is significantly reduced after the initial reparatory process and, therefore, is unlikely to contribute to a persistent fibrotic response.109 CD45-positive monocytes have been identified as a potential source of fibroblasts because they seem to co-express myofibroblast markers110 and inhibition of monocyte recruitment diminished the CF population and myocardial remodeling after MI.111

Several studies have proposed that infiltrating cells are instead likely to consist of a specific phenotype of inflammatory cells, that may not contribute to the cardiac fibroblast population. Both a lineage tracing study using the hematopoietic-specific Vav-Cre line and a study performing genetically labeled bone marrow transplants incorporating more specific markers of fibroblasts have supported this idea, demonstrating that the contribution of circulating hematopoietic cells to the CF population is minimal.24 Future studies will determine whether these data from a pressure-overload heart failure model will extend to models of ischemic heart failure etiology.

**Fibrocytes**

The contribution of cells of hematopoietic origin to the fibroblast population is also under intense investigation after the identification of fibrocytes in the circulation.112 In fact, subsequent studies have reported the contribution of these fibrocytes to the CF population, as well as to the development of cardiac fibrosis in several injury models.42,109,110,113,114 Their pathophysiological relevance to cardiac fibrosis has been suggested in studies linking the inhibition of fibrocyte recruitment to reduced fibrosis and remodeling.110 Fibrocytes represent a unique fibroblast progenitor population that coexpress fibroblast markers, such as procollagen I and vimentin, along with typical hematopoietic markers.115 These circulating fibrocytes seem to originate from hematopoietic stem cells in the bone marrow115; however, their pathophysiological relevance in cardiac disease and fibrosis has yet to be fully characterized.

**Alternate Growth Substrates**

Mechanical stretching of the CF, which potentially occurs secondary to cardiac dilatation or changes in the hemodynamic burden of the heart, may induce expression of profibrotic cytokines and expression of ECM proteins and receptors on CFs.116 Mechanical stress could play a contributory or pre-eminent role for the spontaneous activation observed when CFs are cultured on the stiff surface of standard tissue culture plastic. The elasticity (Young’s Modulus) of most cell culture plastic is >1 GPa, and for glass, this measure exceeds 70 GPa. In contrast, the Young’s Modulus of the normal heart is estimated to be <10 kPa. Thus, the natural growth environment for CFs is many orders of magnitude more elastic than standard cell culture conditions. Attempts to circumvent the issue of spontaneous activation in standard cell culture conditions have focused predominantly on the modulation of growth substrate tensile modulus. Polyethylene glycol-based hydrogels with a physiologically relevant elasticity (=7 kPa) have shown promise in preserving the quiescent fibroblast phenotype of valvular interstitial cells when compared with standard tissue culture polystyrene. Cells grown on this substrate exhibited reduced levels of typical myofibroblast markers, including αSMA and connective tissue growth factor (CTGF).117,118 The PI3K/AKT pathway is upregulated when these cells are mechanically activated by stiff substrates, and activation of this pathway was significantly attenuated in cells grown on the more compliant substrate.118 Using tissue culture substrates with a physiologically relevant tensile modulus will aid in the characterization of fibroblast biology in vitro.

**Therapeutic Targets in Cardiac Fibrosis**

Numerous signaling pathways have been implicated in the early activation of CFs as well as in the pathological remodeling that persists long after the initial injury. Modulation of these signals is of intense scientific interest because they represent potentially novel therapeutic targets or strategies. Here, we explore mediators and signaling pathways known to influence fibroblast function after myocardial injury as well as developing therapeutic strategies to combat pathogenic cardiac fibrosis (Table 2; Figure 3).

**Transforming Growth Factor β**

The TGF-β family of growth factors is perhaps the most extensively studied mediator of fibroblast activation, of which TGF-β1 is likely to play the greatest role in pathological fibrosis.166 TGF-β is known to play a major role in regulating fibrotic processes in many organs, and in fact, serum levels are used as diagnostic tools and also correlate with the severity of chronic liver and kidney diseases.83 TGF-β1 is initially secreted in a complex with latent TGF-β–binding proteins that restrict its activity; this complex is proteolytically cleaved and can be activated in an integrin-mediated process.167,168 The type I TGF-β receptor, which is also known as activin receptor-like kinase (ALK) 5, represents the subtype thought to be predominantly responsible for the fibrotic activities of TGF-β1. The canonical pathway of TGF-β1 signaling involves the phosphorylation of Smad2/3, which subsequently bind Smad4 and translocate to the nucleus. The complex then acts as a transcription factor, inducing the activation of numerous profibrotic genes.169,170 The ability of TGF-β to induce the production of ECM proteins in vitro is thought to depend on Smad3,169,171 and furthermore, fibroblasts isolated from Smad3-deficient mice seem resistant to TGF-β1–induced expression of ECM proteins.172,173 Perhaps equally detrimental to overall cardiac function as the initial infarct, the canonical TGF-β pathway is also activated in the infarct border and remote zones where it mediates the formation of pathological...
reactive fibrosis.\textsuperscript{169–171} Finally, the persistence of activated fibroblasts is thought to be the result of perpetual TGF-β signaling, which may prevent CF apoptosis after the initial injury through Smad-mediated pathways.\textsuperscript{174}

Inhibitors of the TGF-β receptor ALK5 are currently under investigation as potential antifibrotic mediators. ALK5 inhibitors can decrease TGF-β activity, rescuing cardiac dysfunction and ameliorating the remodeling that occurs post-MI.\textsuperscript{119} These inhibitors can also attenuate the development of fibrosis and expression of collagen after pressure overload by transverse aortic constriction, and reduce the expression of collagen after pressure overload by experimental myocardial fibrosis models. Although fibroblast activation and collagen transcript levels were reduced, there were no substantial improvements in overall cardiac function,\textsuperscript{121} and there is evidence that this strategy may actually be the dominant driving force.\textsuperscript{123,137} Further downstream, inhibition of p38 is being actively investigated as potential antifibrotic mediators. ALK5 –induced fibroblast ECM protein production.\textsuperscript{124}

Table 2. Therapeutic Targets and Approaches in Cardiac Fibrosis

<table>
<thead>
<tr>
<th>Target</th>
<th>Approach</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-β</td>
<td>TGF-β receptor 1 (ALK5) inhibition, TGF-β neutralizing antibodies,</td>
<td>Tan et al,\textsuperscript{118} Engebretnsen et al,\textsuperscript{125}</td>
</tr>
<tr>
<td></td>
<td>TGF-β–activated kinase 1 inhibition, and p38 inhibition</td>
<td>Kuwahara et al,\textsuperscript{127} Frantz et al,\textsuperscript{123}</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Davis et al,\textsuperscript{123} Ono et al,\textsuperscript{124} Kompa et al,\textsuperscript{125} and See et al\textsuperscript{126}</td>
</tr>
<tr>
<td>Angiotensin system</td>
<td>ARBs and ACE inhibition</td>
<td>Zou et al,\textsuperscript{127} Diez et al,\textsuperscript{128} Pfeffer et al,\textsuperscript{123} Yang et al,\textsuperscript{130}</td>
</tr>
<tr>
<td>Endothelin system</td>
<td>Endothelin receptor antagonents</td>
<td>Oliveira-Juniior et al,\textsuperscript{121} Galie et al,\textsuperscript{123} Miguel-Carrasco et al,\textsuperscript{123} Duerschmid et al,\textsuperscript{124} Sato et al,\textsuperscript{131} Shimada et al\textsuperscript{134}</td>
</tr>
<tr>
<td>RhoA–SRF–MRTF pathway</td>
<td>SRF inhibition and RhoA inhibition</td>
<td>Leask,\textsuperscript{132} Singh et al,\textsuperscript{132} Sütsch et al,\textsuperscript{136} Rodríguez-Pascual et al,\textsuperscript{124} Kohan et al,\textsuperscript{141} Anand et al,\textsuperscript{142} and Prasad et al\textsuperscript{43}</td>
</tr>
<tr>
<td>TRPC</td>
<td>TRPC6 inhibition and Calcineurin inhibition</td>
<td>Davis et al,\textsuperscript{123} and Kuwahara et al\textsuperscript{143}</td>
</tr>
<tr>
<td>CTGF</td>
<td>CTGF neutralizing antibodies</td>
<td>Szabo et al\textsuperscript{146}</td>
</tr>
<tr>
<td>PDGF</td>
<td>PDGF receptor antagonists and PDGF receptor neutralizing antibodies</td>
<td>Liu et al,\textsuperscript{147} and Liao et al\textsuperscript{148}</td>
</tr>
<tr>
<td>Integrins</td>
<td>α,β, integrin inhibition (lung and liver)</td>
<td>Reed et al\textsuperscript{49}</td>
</tr>
<tr>
<td>Inflammatory signaling</td>
<td>Interferon-γ inhibition</td>
<td>Han et al,\textsuperscript{150} and Marko et al\textsuperscript{151}</td>
</tr>
<tr>
<td>Cardiomyocyte regen.</td>
<td>Induced pluripotent stem cell transplantation and fibroblast reprogramming</td>
<td>Ieda et al,\textsuperscript{152} Qian et al,\textsuperscript{152} Song et al,\textsuperscript{152} and Deb and Ubil\textsuperscript{154}</td>
</tr>
<tr>
<td>Electric communication</td>
<td>Cx43—expressing cardiomyocyte engraftment</td>
<td>Roell et al\textsuperscript{155}</td>
</tr>
<tr>
<td>Adrenergic system</td>
<td>Gα12/13-GRK2 inhibition (paroxetine, jAρKct, and gallein), RhoA inhibition, and β-arrestin inhibition</td>
<td>Robinson and Pifchet\textsuperscript{156} Li et al,\textsuperscript{157} Thal et al,\textsuperscript{158} Schumacher et al,\textsuperscript{159} Raake et al,\textsuperscript{159} Rengo et al,\textsuperscript{159} Belmonde et al,\textsuperscript{159} Casey et al,\textsuperscript{160} Kamal et al,\textsuperscript{161} and Kamal et al\textsuperscript{162}</td>
</tr>
</tbody>
</table>

ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; CTGF, connective tissue growth factor; Cx43, connexin 43; GRK2, G-protein-coupled receptor kinase 2; MRTF, myocardin-related transcription factor; PDGF, platelet-derived growth factor; SRF, serum response factor; TAK, transforming growth factor-β–activated kinase; and TRPC, transient receptor potential channel.

In addition to the Smad-mediated pathways, TGF-β can also induce noncanonical signaling that involves several mitogen-activated protein kinases, including c-Jun N-terminal kinase, and p38.\textsuperscript{177–179} This pathway involves the activation of TGF-β–activated kinase (TAK) 1, which is thought to contribute to pathological cardiac remodeling because cardiac overexpression of constitutively active TAK1 induces cardiac hypertrophy and heart failure.\textsuperscript{177–179} Although the myofibroblast-activating properties of TGF-β have previously been attributed to the canonical signaling pathway, growing evidence suggests the noncanonical pathway may actually be the dominant driving force.\textsuperscript{123,137} Thus, attempts to prevent this noncanonical signaling may prove efficacious for the treatment of fibrosis and heart failure. The TGF-β noncanonical signaling pathway is thought to propagate primarily through the type II TGF-β receptor, given that cardiomyocyte-specific deletion of the type II TGF-β receptor has resulted in reduced fibrosis and remodeling in the transverse aortic constriction model of heart failure.\textsuperscript{180} As the main effector of the TGF-β noncanonical pathway, TAK1 also represents a viable therapeutic target, as inhibition of TAK1 reduced TGF-β–induced fibroblast ECM protein production.\textsuperscript{124} Further downstream, inhibition of p38 is being actively investigated for its antifibrotic potential. Inhibitors of p38 signaling can attenuate TGF-β–induced myofibroblast activation and reduce the expression of collagen, fibronectin, and αSMA in mouse embryonic fibroblasts; moreover, overexpression of p38 can induce the myofibroblast transition.\textsuperscript{123} In vivo, inhibition of p38 reduces fibrosis and the expression of αSMA after MI.\textsuperscript{125,126} Several clinical trials evaluating the efficacy of p38
inhibition have begun in patients after acute MI. In the study of Losmapimod Treatment on Inflammation and Infarct size (SOLSTICE) phase II trial, the p38 inhibitor losmapimod was well tolerated in non-ST-segment–elevation MI patients with no major liver toxicities observed. Although infarct size was nonsignificantly reduced, patients receiving losmapimod experienced fewer cardiac events.181 These findings provide strong evidence for the therapeutic potential of targeting the TGF-β noncanonical signaling pathway, specifically through modulation of TAK1 and p38, in the treatment of cardiac fibrosis.

Renin–Angiotensin System

The renin–angiotensin–aldosterone system, of which angiotensin II (Ang II) seems to be the predominant effector, promotes many physiological and pathological functions, including the development of cardiac fibrosis.182,183 The Ang II type 1 receptor (AT1R) mediates many of the effects of Ang II in fibroblasts, including cell proliferation, migration, and the induction of ECM protein synthesis.184,185 Cardiac Ang II levels are quickly elevated after injury, and stimulation of CFs by Ang II induces proliferation and the expression of collagen.186,187 Renal renin–angiotensin–aldosterone system activity, which is reflected by urinary angiotensinogen levels, directly correlates with the extent of renal fibrosis and deterioration of renal function in patients with chronic kidney disease.188 Ang II is also intimately involved with the inflammatory response because it is expressed and activated by macrophages and myofibroblasts.189 It is thought that Ang II is also involved with TGF-β signaling, both in cardiomyocytes and in CFs. Specifically, Ang II activation of ATR1 induces the expression TGF-β1, and it is thought that TGF-β is required for Ang II to induce both cardiac hypertrophy and fibrosis.190,191 Furthermore, Ang II–induced expression of collagen in CFs requires TGF-β/Smad and mitogen-activated protein kinase signaling.186,189

Hemodynamic burden, chronic fibrotic remodeling, and tissue stiffening after a myocardial injury can stimulate the release of endogenous Ang II from cardiomyocyte stores; however, it is now recognized that this mechanical stress can contribute directly to the activation of the AT1R.127 Although HEK293 and COS7 cells do not natively respond to mechanical stretch, expression of the AT1R confers this ability, as seen by an increase in the activation of ERK, suggesting that the AT1R is itself a mechanical sensor. Mechanical stretching of cardiomyocytes isolated from ATG null mice, which do not express endogenous Ang II, also resulted in ERK activation.
In addition, cardiac hypertrophy in ATG^- mice was induced by pressure overload, indicating that mechanical stress can induce hypertrophy even in the absence of Ang II. Of note, these mechanical sensing abilities seem to be specific to the AT1R because other G-protein–coupled receptors (GPCRs) do not respond to mechanical stretch. A similar phenomenon occurs in CFs because these cells are highly susceptible to variations in their mechanical microenvironment. This stretch-induced activation of the AT1R can be inhibited by the Ang II receptor blocker candesartan, revealing a potential antihypertrophic and antifibrotic role for this class of drugs. Because candesartan will reduce blood pressure and thus cardiac load, the mechanism by which it attenuates fibrosis remains unclear and may not necessarily be due to direct inhibition of pathologically activated CFs.

Although not approved for the treatment of cardiac fibrosis, inhibitors of angiotensin signaling, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, have already demonstrated significant efficacy in the treatment of heart failure, frequently reducing cardiac fibrosis. Inhibitors of angiotensin signaling, including angiotensin-converting enzyme inhibitors, inhibitors of angiotensin II (Ang II) receptor and angiotensin II receptor blockers, have already demonstrated significant efficacy in the treatment of heart failure, frequently reducing cardiac fibrosis. Further studies will be necessary to determine if ET-1 and its receptors will become clinically viable antifibrotic therapeutic targets.

The endothelin family of peptides is typically recognized for its vasoconstrictive properties and is now beginning to be appreciated for its potential role in promoting tissue fibrosis. Although originally thought to be secreted predominantly by endothelial cells, endothelin-1 (ET-1) is now understood as a significant profibrotic peptide released by both inflammatory cells and fibroblasts in the lung. The endothelin system also plays a major role in kidney disease because ET-1 production is stimulated in disease downstream to both the sympathetic nervous system and the renin–angiotensin–aldosterone system. There exist two known receptors for ET-1 in the heart, the ETA and ETB receptors, which have been shown to play differing and sometimes opposing roles. These receptors are primarily expressed by endothelial cells; however, new data define expression on multiple cell types including cardiomyocytes and CFs, along with some immune cells, such as macrophages. Importantly, ET-1 activation of the ETA receptor is known to increase collagen production in isolated human CFs. Furthermore, myofibroblasts isolated from scar tissue after experimental MI possess elevated levels of ET-1, suggesting an important function for endothelin within these cells. Although known to have fibroblast-activating properties of its own, ET-1 also acts as a downstream mediator of both Ang II and TGFβ to promote myofibroblast persistence in pulmonary fibrosis. ET-1 signaling is thought to interact with Ang II as well. For example, the development of cardiac fibrosis and hypertrophy in response to Ang II stimulation is impaired in mice in which ET-1 is ablated in endothelial cells. It is thought that these factors are mechanistically linked through the activation of ERK1/2 and the myocardial-related transcription factor (MRTF) A.

Endothelin antagonists are currently approved for the treatment of pulmonary hypertension, and many think they will be additionally efficacious in the treatment of pathological fibrosis in the heart. Endothelin receptor blockade has been incorporated extensively both experimentally and in the clinic for its salutary role in the treatment of hypertension. Bosentan, a nonselective endothelin receptor antagonist, although used clinically for the treatment of pulmonary hypertension, can improve cardiac function and reduce infarct size after myocardial ischemia/reperfusion injury in rats. Preliminary trials in humans had demonstrated beneficial hemodynamic and cardiac effects in patients with end-stage heart failure. However, subsequent clinical trials evaluating endothelin receptor antagonists on coronary artery disease and heart failure have not met primary end points, perhaps because of inefficient selection of potential responders before the initiation of major clinical trials. Although the reasons for these discrepancies remain unclear, manipulation of ET-1 signaling seems promising. Next generation ETR subtype-specific antagonists, such as ambrisentan and darusentan that are proving to be highly beneficial in the treatment of pulmonary hypertension, may prove more efficacious and help define receptor specificity that may be required for salutary effects. Further studies will be necessary to determine if ET-1 and its receptors will become clinically viable antifibrotic therapeutic targets.

**RhoA–MRTF–SRF Signaling Pathway**

Serum response factor (SRF), a member of the MADS box-containing family of transcription factors, is critically involved in the regulation of myofibroblast activation, given that numerous SRF-binding sites are located within the promoter regions of genes responsible for fibroblast activation. Experiments in bleomycin-injured lung tissue have demonstrated upregulation of SRF expression in isolated myofibroblasts, and overexpression of SRF can induce the transformation of both lung and CFs. SRF interacts with cofactors such as members of the MRTF family of transcription factors, which translocate to the nucleus and bind SRF to regulate its transcriptional efficacy. In CFs, MRTF-A overexpression alone can induce the myofibroblast transition and the expression of αSMA; conversely, MRTF-A ablation in vivo reduces the fibrotic response after MI.
These findings have revealed TRPC6-mediated Ca\(^{2+}\) entry and expression is induced in fibroblasts stimulated by TGF-\(\beta\).\(^{213,214}\) Activity during the fibrotic response, and its expression induced Rho–MRTF–SRF signaling along with its canonical and noncanonical signaling pathways. Perhaps the inhibition of RhoA, using compounds such as fasudil, presents a potential antifibrotic strategy that complements those described above.

**Transient Receptor Potential Channels**

Receptor-activated Ca\(^{2+}\) entry is induced after the activation of GPCRs and receptor tyrosine kinases, including the AT1R or TGF-\(\beta\)-receptor, leading to the activation of calcineurin and nuclear translocation of the nuclear factor of activated T cells family of transcription factors.\(^{210}\) The transient receptor potential proteins are the channels responsible for this receptor-mediated Ca\(^{2+}\) entry; the canonical transient receptor potential channels (TRPC) specifically couple receptor-phospholipase C signaling pathways to Ca\(^{2+}\) entry\(^{211}\) and are upregulated in mice subjected to myocardial pressure overload.\(^{145}\) Cardiomyocyte-specific overexpression of TRPC6 resulted in cardiomyopathy and promoted nuclear factor of activated T cells–dependent promoter activity. Furthermore, siRNA knockdown of TRPC6 reduced hypertrophic signaling in response to ET-1, suggesting a role of TRPC6 in the GPCR-dependent activation of the calcineurin/NFAT pathway.\(^{215}\)

Recently, the TRPC6 channel was identified in an unbiased genome-wide screen as an important regulator of myofibroblast activation.\(^{123}\) In primary fibroblasts, TRPC6 overexpression induced the expression of myofibroblast marker genes, and genetic ablation conferred resistance to TGF-\(\beta\)-and Ang II–dependent myofibroblast transformation.\(^{123}\) Furthermore, overexpression of a constitutively active calcineurin in Csfs induced the myofibroblast transition, whereas inhibition of calcineurin blocked TRPC6-mediated transformation, indicating a functionally relevant interaction of these proteins in Csfs.\(^{123}\) These findings have revealed TRPC6-mediated Ca\(^{2+}\) entry and activation of the calcineurin/NFAT signaling pathway as novel regulatory mediators in the activation of fibroblasts, and suggest that their inhibition may represent an important antifibrotic therapeutic strategy.

**Connective Tissue Growth Factor**

CTGF belongs to the CCN family (the acronym comes from the first 3 members of the family that were found: CYR61 (cysteine-rich angiogenic inducer 61 or CCN1), CTGF (connective tissue growth factor or CCN2), and NOV (neuroblastoma overexpressed or CCN3) of matricellular proteins, which are dynamically expressed nonstructural proteins of the ECM.\(^{212}\) This family of proteins is thought to play a significant regulatory role in the ECM to modulate cell surface receptors and their responses to cytokines, growth factors, and proteins of the ECM.\(^{212}\) CTGF is a well-characterized mediator of TGF-\(\beta\) activity during the fibrotic response, and its expression is induced in fibroblasts stimulated by TGF-\(\beta\).\(^{213,214}\)

Furthermore, CTGF is strongly upregulated both in human heart failure and in animal models associated with myocardial fibrosis.\(^{213,215}\) Interestingly, induction of CTGF after injury has been observed before the upregulation of TGF-\(\beta\) or deposition of ECM proteins, suggesting an important role in these processes.\(^{216}\) CTGF also seems to play a significant role directly in isolated Csfs, as evidenced by a reduction of various chemokines, matrix metalloproteinases, ECM proteins, and cell adhesion proteins in Csfs in which CTGF is ablated using siRNA.\(^{237}\) Although studies targeting CTGF in animal models of heart failure are relatively limited, preliminary studies in a pressure-overload model have suggested efficacy of CTGF neutralizing antibodies in reducing cardiac remodeling and dysfunction, concomitant with attenuated collagen deposition.\(^{146}\) These data indicate that the pursuit of therapies targeting CTGF may be of clinical interest for the treatment of cardiac fibrosis.

These data are in stark contrast to a recent study investigating the mechanism of CTGF and definitively characterizing its role in cardiac injury. Several transgenic mouse lines were developed that included heart-specific CTGF knockouts and overexpressors in combination with constitutively active TGF-\(\beta\) and fibroblast-specific CTGF knockout mice. Surprisingly, neither gain nor loss of CTGF affected overall cardiac function or the fibrotic response in multiple models of cardiac injury. However, modulation of CTGF did seem to slightly affect the response to TGF-\(\beta\) in a pressure-overload model, suggesting a potential interaction between these factors.\(^{218}\) As described above, CTGF is thought to play an important functional role with TGF-\(\beta\) to regulate the fibrotic response, but recent data suggest that CTGF is of limited importance as a TGF-\(\beta\) effector and thus may no longer represent an important therapeutic target for the treatment of cardiac fibrosis and heart failure.

**Platelet-Derived Growth Factor**

The PDGF family of growth factors is a group of proteins originally recognized for their ability to regulate cell proliferation in smooth muscle cells. Expression of the PDGF family is significantly increased in endothelial cells, macrophages, and myofibroblasts after MI.\(^{219}\) Enhanced expression of both the ligands and the receptors occur concomitantly with inflammatory and fibrogenic responses after MI, identifying a potential role in the regulation of cardiac repair.\(^{219}\) Stimulation by PDGF is known to enhance CsF proliferation, and also enhances TGF-\(\beta\) expression in vitro.\(^{220,221}\) Similarly, cardiac-specific overexpression of PDGF significantly elevates TGF-\(\beta\) transcription and promotes the development of cardiac fibrosis.\(^{122}\)

The disruption of PDGF signaling is currently under active investigation for the treatment of myocardial fibrosis. The tyrosine kinase inhibitor imatinib, typically recognized for its antitumorigenic properties, can also suppress PDGF signaling by acting as an antagonist against the PDGF receptor. In an MI model of heart failure, imatinib reduced the expression of fibrogenic mediators, including TGF-\(\beta\) and collagen I, significantly reduced fibrotic scar formation and mildly rescued cardiac dysfunction.\(^{147}\) A neutralizing PDGF receptor antibody has also been shown to attenuate atrial fibrosis in a pressure-overload model of heart failure.\(^{148}\) Collectively, these data implicate PDGF in the development of cardiac fibrosis,
probably through the induction of TGF-β, and additionally present PDGF inhibition as a potential approach for antifibrotic therapy.

Integrins
Integrins are transmembrane proteins comprised of α and β subunits that mediate interactions between the extracellular environment and the actin cytoskeleton. CFs express a wide variety of integrin subtypes that mediate multiple cellular functions, including proliferation, migration, adhesion, differentiation, and apoptosis.223–225 Furthermore, it has been reported in cultured myofibroblasts that integrins are required for the activation of latent TGF-β.168 The integrin-mediated transformation of myofibroblasts is thought to occur through activation of mitogen-activated protein kinase signaling cascades, including ERK1/2 and p38.226 This regulation of TGF-β activation may be one potential mechanism causing the persistence of myofibroblasts within fibrotic scars, and may offer a target for ameliorating adverse myocardial remodeling after injury.167,174 Strategies aimed at blocking the function of integrins have shown preliminary success in limiting maladaptive remodeling. For example, small molecule targeting of the α,β integrin, which is highly expressed in activated fibroblasts, attenuated pulmonary and liver fibrosis through a mechanism involving the inhibition of TGF-β activation.149 It is possible that therapeutic approaches targeting various integrin subtypes could be therapeutically useful for the treatment of numerous diseases characterized by excessive tissue fibrosis.

Inflammation/Interferon Receptors
Inflammation is an essential mediator of the reparative response to an acute cardiac insult. Numerous inflammatory cells, including neutrophils and macrophages, infiltrate the site of injury where various proinflammatory cytokines are released, such as tumor necrosis factor α, IL-1β, and IL-6, and play an important role in the initial induction of resident fibroblast proliferation and myofibroblast activation.227 In addition to their direct release of ECM components, activated CFs also express numerous cytokines and growth factors that affect wound healing via autocrine and paracrine mechanisms.228 Cytokine expression by CFs is markedly upregulated after acute myocardial injury, including the expression of the proinflammatory cytokines IL-1β and IL-6. IL-1β promotes fibroblast migration through increasing the expression of proteins involved in ECM turnover, including matrix metalloproteinases,229 and IL-6 is known to increase fibroblast proliferation and myocardial fibrosis.230

Interferons (IFNs) are a family of cytokines that cause a myriad of biological responses and, in addition to immune cells, they can be secreted by other cell types such as CFs.231,232 However, the role of IFNs in fibrosis, specifically IFN-γ, remains somewhat controversial.233 In IFN-γ knockout mice challenged with Ang II, there was a reduction in the myofibroblast marker αSMA.234 Similarly, mice null for the IFN-γ receptor exhibit a decrease in cardiac hypertrophy and fibrosis, as well as a reduction in the infiltration of macrophages and T cells.151 Because extensive data have demonstrated a critical role of inflammation in the fibrotic response, inhibiting these inflammatory mediators may prove efficacious in the treatment of cardiac fibrosis.

GPCR/Adrenergic Signaling
The adrenergic system plays a fundamental role in the physiological regulation of the myocardium, but chronic overstimulation can induce both cardiac hypertrophy and fibrosis.234 Although several subtypes of the β-adrenergic receptor (β-AR) are expressed in the heart, the β2-AR seems to be the form that is predominantly expressed by CFs.235 Chronic stimulation of this receptor can induce cell proliferation, collagen secretion, migration, and transformation to the myofibroblast phenotype.235

It is well established that acute stimulation of the β-AR increases the levels of cAMP, which can modulate proliferation236 as well as inhibit the synthesis and secretion of various forms of collagen.237,238 In addition, elevated cAMP levels can inhibit the transformation of CFs to myofibroblasts induced by stimulation with TGF-β.239 Recent studies indicated that failing human CFs isolated from patients with heart failure had higher baseline collagen synthesis that was not inhibited by β-agonist stimulation. Furthermore, β-AR signaling was markedly uncoupled and associated with increased expression and activity of GPCR kinase 2 (GRK2).237 Similarly, knockdown or inhibition of GRK2 restored β-agonist–stimulated inhibition of collagen synthesis and decreased collagen synthesis in response to TGF-β stimulation, indicating a significant role for GRK2 in the regulation of collagen synthesis and maladaptive ventricular remodeling.240 GRK2 is also recognized for its role as a RhoA-activated scaffold protein for the ERK mitogen-activated protein kinase cascade, which may have implications in the development of hypertension,156 and also suggests potential interactions with profibrotic mediators, including TGF-β, Ang II, and ET-1. GRK2 is typically recognized for its role in the downregulation of β-ARs, predominantly through the recruitment of β-arrestin, which is also significantly upregulated in adult human CFs isolated from failing left ventricles.157 Enhanced β-arrestin signaling in CFs seems to be deleterious in that it promotes a profibrotic phenotype via the uncoupling of β-ARs and potentiates ERK and Smad signaling downstream of TGF-β.157 Targeting GRK2, RhoA, and β-arrestin may represent plausible therapeutic strategies for the prevention of myocardial fibrosis.

Several approaches for specifically targeting GRK2 have been developed, all of which have shown some promise in reducing the fibrotic response concomitant with protection against overall cardiac dysfunction. The selective serotonin reuptake inhibitor paroxetine was recently identified as an inhibitor of GRK2.158 Paroxetine is known to reverse left ventricular dysfunction after MI, and reduce both immediate infarct and remote region fibrosis, albeit at a dose substantially in excess of that used in humans.159 These data suggest that targeting GRK2 signaling may be a potent antifibrotic approach. The idea of inhibiting the interaction between GRK2 and G-protein βγ subunits has been investigated in several models of heart failure, using either small molecules or a truncated form of GRK2 known as βARKct. The βARKct peptide has shown promise in preventing myocardial dysfunction in both small and large animal models of heart failure.160,161
The small molecule Gβγ-GRK2 inhibitor gallen has demonstrated the ability to improve cardiac function and reduce the fibrotic response in several murine models of heart failure. Of further interest, the introduction of galen attenuated pathological renal abnormalities, including renal dysfunction, tissue damage, and fibrosis, which occur secondary to myocardial pressure-overload injury (Blaxall Lab, unpublished data, 2016). Although the mechanism of GRK2 and Gβγ-GRK2 inhibition within CFs has yet to be fully delineated, GRK2 represents an exceptionally important target for therapeutic interventions directed against myocardial fibrosis.

Fibroblasts for Cardiomyocyte Regeneration

With the advent of stem cell–based therapeutics for the treatment of cardiovascular disease, there is now a growing interest in the development of reprogramming techniques to induce the transformation of fibroblasts into functional cardiomyocytes. Although still in its infancy, this technique relies on the creation of induced pluripotent stem cells, which can be differentiated in vitro to potentially generate patient-specific cardiomyocytes for subsequent introduction into the failing or infarcted heart. Newer methods are beginning to allow for the direct reprogramming of fibroblasts into cardiomyocytes in vivo through the administration of a specific combination of transcription factors. Unfortunately, with these current approaches, the number of fibroblasts that successfully transition into healthy cardiac muscle cells in vivo still remains small, and some reports suggest this may not be a viable approach.

Electrical Communication

A new area of study that has previously been thought to be of little physiological relevance is the electrical communication between CFs and cardiomyocytes. The relatively large membrane resistance of interstitial CFs renders these cells suitable for the conduction of electric signals. Seminal ex vivo studies have demonstrated a robust physical communication with adjoining cardiomyocytes, although the physiological relevance of such interactions in vivo is still under investigation. It is now understood that CFs are capable of electrically coupling with cardiomyocytes, which influences their electric properties, and this likely occurs through the action of connexin 43, the subtype predominantly expressed by cardiomyocytes. The belief is this will allow CFs to form bridges linking regions of myocytes to aid in the synchronization of myocyte contractions.

The development of fibrosis is known to disrupt the normal arrangement of myocytes and fibroblasts, and as such, has serious implications in the development of ventricular arrhythmias in patients after an acute myocardial injury. Modulation of the interactions between CFs and cardiomyocytes may prove to be an interesting therapeutic approach.

Of note, the risk of postinfarction ventricular tachycardia is significantly reduced after the engraftment of embryonic cardiomyocytes engineered to express connexin 43, probably because of the improved electric coupling between the surrounding myocardium and the infarct region. This therapeutic avenue will need to be approached cautiously though, as there are conflicting data on the effect of CF density on the impact of CF–cardiomyocyte coupling. Although the targeting of CF–cardiomyocyte electric coupling holds potential for the effective treatment of cardiac arrhythmogenesis, the variable responses in different clinical settings and intricacies of this signaling will require full examination before these types of interventions can become clinically viable.

Conclusions

It is abundantly clear that a deeper understanding of CFs will be critical to achieving exciting advancements in the treatment of cardiac fibrosis and disease. A limited knowledge of the role of this essential and dynamic cell type continues to hinder progress in the design and application of meaningful new therapies. The development of more specific in vivo approaches along with the identification of novel biomarkers will allow for greater investigation of this important cell population. Furthermore, unraveling the intricate mechanisms underlying this fibrotic signaling is of utmost importance for the development of effective therapies for the treatment of cardiac fibrosis. Therapeutic interventions targeting CFs and the pathological fibrosis they promote will inevitably lead to significant advancements in the treatment of heart failure.

Acknowledgments

We wish to acknowledge Jeffery Molkentin for his astute suggestions during the development of this review.

Sources of Funding

This work was supported by National Institutes of Health grants R01 HL091475, R01 HL129772, R01 HL132551, R01 GM097347, U54 HL119810 (B.C. Blaxall), and P01 HL069779 (B.C. Blaxall, J. Robbins, and K.E. Yutzey), an American Heart Association Postdoctoral Fellowship (F.A. Kamal), and a Predoctoral Fellowship from the Pharmaceutical Research and Manufacturers of America Foundation (J.G. Travers).

Disclosures

None.

References


Identification and characterization of a novel Schwann and outflow tract progenitor: A transgenic mouse model.

Travers et al. New Frontiers in Cardiac Fibrosis 1035


180.
179.
176.
175.
174.
169.
168.
166.
1038


Travers et al. New Frontiers in Cardiac Fibrosis


251. Gaudesius G, Miragoli M, Thomas SP, Rohr S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res. 2003;93:421–428. doi: 10.1161/01.RES.0000089258.40661.0C.

252. Kohl P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ Res. 2003;93:381–383. doi: 10.1161/01.RES.0000091364.90121.0C.


Cardiac Fibrosis: The Fibroblast Awakens
Joshua G. Travers, Fadia A. Kamal, Jeffrey Robbins, Katherine E. Yutzey and Burns C. Blaxall

Circ Res. 2016;118:1021-1040
doi: 10.1161/CIRCRESAHA.115.306565

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/118/6/1021

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/